{"links":{"html":"https://www.erudio.com/reports/ifm2022-01-nct06353022","json":"https://www.erudio.com/reports/ifm2022-01-nct06353022.json","markdown":"https://www.erudio.com/reports/ifm2022-01-nct06353022.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"ifm2022-01-06353022"}},"request":"https://www.erudio.com/contact?report=ifm2022-01-06353022"},"offer":{"cited_commentary_sources":4,"verified_hcp_statements":15,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":3,"optional":true,"price_per_verified_person_usd":15,"price_usd":45,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"ifm2022-01-nct06353022"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ifm2022-01-06353022","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ifm2022-01-nct06353022","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T15:26:40.329377Z","notify_subscribers":false,"status":"corrected","summary":"The trial is named IFM 2022-01, as its sources and the report name it (was IFm2022-01)"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":2},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Rate of sustained MRD negativity (NGS, 10^-5)"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":4,"title":"Primary endpoint: Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":0,"title":"The comparison"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":3,"title":"Treatment duration and stopping"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":2,"title":"ASCT and the route to upfront T-cell redirection"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"High-risk and ultra-high-risk unmet need"},{"claim_count":2,"coverage":"discussed","id":"A4","source_count":1,"title":"Future bortezomib removal and patient experience"}],"counts":{"cited_sources":4,"claims_by_expression_type":{"interpretation":4,"opinion":7,"question":1,"restatement":1,"uncertainty":2},"claims_by_kind":{"attributed_opinion":7,"source_observation":8},"clinician_statements":7,"evidence_units":5,"findings":5,"people_cited":3,"people_identity_verified":3,"people_total":3,"screened_sources":8,"verified_claims":15},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":2,"links":{"context":1,"support":4},"ma_question":true,"named_voices":3,"passages":5,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Enthusiasm for early MRD conversion is qualified by the distinction between undetectable and sustained MRD"},{"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Rapid responses prompt a question about two years of exposure, alongside concern about cumulative toxicity"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"ASCT is questioned, while the route to upfront T-cell redirection remains unsettled"},{"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"High-risk and ultra-high-risk patients qualify the optimistic frontline outlook"},{"id":"F5","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"Avoiding neuropathy is part of one speaker's longer-term vision for frontline treatment"}],"medical_affairs_question":"What evidence would justify shorter exposure or different sequencing while preserving durable benefit and limiting harm?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Early MRD conversion does not establish persistence"},{"id":"section-2","level":2,"title":"Duration: a two-year question is different from a finite-treatment preference"},{"id":"section-3","level":2,"title":"Sequencing: transplant questions coexist with uncertainty about how to move redirection upfront"},{"id":"section-4","level":2,"title":"High-risk uncertainty limits a uniform-benefit reading"},{"id":"section-5","level":2,"title":"Neuropathy avoidance is a future treatment goal, not a trial outcome"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1}],"id":"T1","label":"Primary endpoint: Rate of sustained MRD negativity (NGS, 10^-5)"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T2","label":"Primary endpoint: Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T15:26:40.329377Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T15:37:29Z","record_hash":"ffedb67e4025c777ccba7a55dd8710c0ed3bd8600cfb6a607068522694f96e3e","release_hash":"a7ac1b5d4e0056a8c2c694020a86232e35ca63b6e9e151df443d8a60768582d9","report_id":"erudio-nct06353022","run_id":"bfd29951-b6ee-4305-ab7f-193352a451d3","schema_version":"5.0","slug":"ifm2022-01-06353022","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"IFM 2022-01 examines whether using residual disease testing to guide T-cell redirectors after induction can deepen responses in newly diagnosed multiple myeloma. Clinicians in the sources reviewed for this edition question the place of autologous stem-cell transplantation, while the route to upfront T-cell redirection remains unsettled. Early MRD conversion draws enthusiasm, while its distinction from sustained negativity draws scrutiny. How these responses should inform transplantation and the timing of T-cell redirection remains open.","meta_description":"8 sources screened · 15 verified statements (7 from clinicians verified by NPI or staff page) from 4 sources · 5 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-c7f4f3308e6958ea718f"],"id":"F1","paraphrase":"The methodological question addressed in X-thread commentary is how to distinguish early MRD clearance from sustained negativity.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"unavailable"},"source_channel":"x_thread","source_date":"2026-09-25","title":"Enthusiasm for early MRD conversion is qualified by the distinction between undetectable and sustained MRD"},{"cited_claim_ids":["claim-118c07bf8fe939becc06"],"id":"F3","paraphrase":"The evidence-assessment question arising from X-thread commentary is what evidence would be needed to evaluate changes in transplantation practice.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"unavailable"},"source_channel":"x_thread","source_date":"2026-09-25","title":"ASCT is questioned, while the route to upfront T-cell redirection remains unsettled"}]},"publication":{"approved_at":"2026-10-28T15:37:29Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-28T20:58:29Z","summary":"The trial is named IFM 2022-01, as its sources and the report name it (was IFm2022-01)"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":8},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","3 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","These views are not a representative survey of HCP opinion. Reposts do not establish additional independent clinician views or endorsement.","Discussion that omits the trial name or uses different wording may be missing. Some portions of the X and video discussions were not fully assessed, so additional or differing views may be absent.","The video speaker cannot be identified from the spoken material reviewed; the publisher's description does not resolve that uncertainty.","No publication for NCT06353022 was found for this edition, and the registry did not list a protocol. The comments cannot substitute for a full assessment of study methods or outcomes.","The regulatory material reviewed was incomplete and did not include an exact talquetamab label. The safety discussion is not a comprehensive risk assessment."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":4},"count":4,"evidence_window":{"end":"2026-09-26","start":"2026-09-25"},"retrieval_snapshot":"2026-10-28T15:10:32.659363Z","timeline":[{"count":4,"week":"2026-W39"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06353022:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06353022:context","quote_policy":"short_quote_link_out"},{"id":"openfda:54e0f974-ccee-44ea-9254-40e9883cee1e:20260310","quote_policy":"short_quote_link_out"},{"id":"openfda:1b2716cf-24b4-4157-a218-58ede63917bd:20260527","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vfwxbyybcmuhaderu7owb6sf-3mwdhinqlgg2j","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103428389495337336:9303f794-3920-48aa-a443-bb2c87e13c0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103430145109569738:ca4a55b1-c320-4403-adca-b71ecce2febc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103431681692594405:b37df672-0f11-4ef3-9102-bfbe798373fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103788258346066275:5c5996d3-12b2-4a64-ae34-b020d3b61493","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105020950383366165:cd3e4bf4-3917-4f04-88a1-c5da55e549b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113652747384107191:b0bcdbeb-f501-4a90-8b14-ae42f20991bf","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ASEjroGxtuw","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":8},"count":8,"evidence_window":{"end":"2026-10-23","start":"2026-09-25"},"retrieval_snapshot":"2026-10-28T15:10:32.659363Z","timeline":[{"count":6,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Tecvayli"],"label":"teclistamab","slug":"teclistamab"},{"brand_names":["Talvey"],"label":"talquetamab","slug":"talquetamab"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"IFM 2022-01","aliases":["IFM 2022-01","IFm2022-01","Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)"],"brief_title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","collaborators":["Janssen Pharmaceutica"],"conditions":["Multiple Myeloma"],"enrollment":{"count":103,"type":"ESTIMATED"},"interventions":[{"name":"Teclistamab","synonyms":["No more information"],"type":"DRUG"},{"name":"Talquetamab","synonyms":["No more information"],"type":"DRUG"},{"name":"Lenalidomide","synonyms":["No more information"],"type":"DRUG"},{"name":"Bortezomib","synonyms":["No more information"],"type":"DRUG"},{"name":"Daratumumab","synonyms":["No more information"],"type":"DRUG"},{"name":"Dexamethasone","synonyms":["No more information"],"type":"DRUG"}],"nct_id":"NCT06353022","official_title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-04-26","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Rate of sustained MRD negativity (NGS, 10^-5)","timeFrame":"38 months"},{"measure":"Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)","timeFrame":"38 months"}],"registry_last_updated":"2026-03-17","registry_url":"https://clinicaltrials.gov/study/NCT06353022","short_name":"IFM 2022-01","short_name_basis":"canonical_name","sponsor":"Nantes University Hospital","start_date":{"date":"2024-06-26","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"RC23_0267","type":"sponsor_study_id"},{"id":"2023-508310-41","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}